F1 Oncology Changes Name To EXUMA Biotech; Announces New Round Of Financing To Advance Cellular Therapies
F1 Oncology Changes Name To EXUMA Biotech; Announces New Round Of Financing To Advance Cellular Therapies
03/12/20, 3:33 PM
Location
EXUMA Biotech Corp. (formerly F1 Oncology), a clinical-stage biotechnology company discovering and developing CAR-T therapies for solid and liquid tumors, today announced a $19M Series B round of financing that includes new investments by MSD Partners and F1 BioVentures, as well as conversion of notes held by individual investors.
Company Info
Location
west palm beach, florida, united states
Additional Info
EXUMA Biotech Corp is a private Delaware corporation formed in November 2015 with operations in West Palm Beach, Florida and international affiliates in the Cayman Islands and Shanghai, China. EXUMA leverages its globally integrated science, development and informatics teams located across multiple time zones to accelerate the design, high-throughput screening, discovery and development of Chimeric Antigen Receptor T cell (CAR-T) candidates for both solid and liquid tumor malignancies. The company is developing logic gated CAR-T platforms to advance TME-restricted cellular therapies for solid tumors, platforms that will allow for same-day, rapid point of care (rPOC) administration for solid or liquid tumors, and highly scalable systems for global therapy deployment, beginning in Asia. Learn more at exumabio.com.